Global Information
회사소개 | 문의 | 위시리스트

발기부전 : 파이프라인 리뷰

Erectile Dysfunction - Pipeline Review, H1 2019

리서치사 Global Markets Direct
발행일 2019년 02월 상품 코드 232812
페이지 정보 영문 109 Pages
가격
US $ 2,000 ₩ 2,308,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,616,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,924,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


발기부전 : 파이프라인 리뷰 Erectile Dysfunction - Pipeline Review, H1 2019
발행일 : 2019년 02월 페이지 정보 : 영문 109 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

발기부전(ED)이란 남성이 성교에 필요한 만큼 발기를 유지할 수 없는 장애를 가리키며 성향 불능증이라고도 불립니다. 질병 소질에는 혈연, 체중 과잉, 상해, 마약·주류 섭취, 약물요법(항우울제, 항히스타민제, 고혈압 치료제, 진통제, 전립선암 치료제 등) 등이 포함됩니다.

세계 각국에서의 발기부전(ED : Erectile Dysfunction) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발 및 출시의 최신 동향, 각 임상시험 단계에 있는 제품 목록, 주요 기업 개요, 주요 치료제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

목차

서론

  • 분석 범위

발기부전(ED) 개요

치료제 개발

  • 발기부전용 파이프라인 제품 : 개요
  • 발기부전용 파이프라인 제품 : 비교 분석

각 기업에서 개발중인 발기부전 치료제

대학/연구기관에서 연구중인 발기부전 치료제

파이프라인 제품 개요

  • 후기 단계 제품
  • 임상시험 단계 제품
  • 초기 단계 제품
  • 불명확한 단계에 있는 제품

발기부전 치료제 : 개발중인 제품 목록(기업별)

발기부전 치료제 : 연구중인 제품 목록(대학/연구기관별)

발기부전 치료제 개발에 참여하고 있는 기업

  • Acorda Therapeutics, Inc.
  • Apricus Biosciences, Inc.
  • Biopharm GmbH
  • Corridor Pharmaceuticals Inc.
  • Futura Medical Plc
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Humanetics Corporation
  • IntelGenx Corp.
  • Mezzion Pharma Co. Ltd.
  • 타나베Mitsubishi 제약
  • Monosol Rx, LLC
  • NAL Pharmaceuticals Ltd.
  • Pacific Therapeutics Ltd.
  • Palatin Technologies, Inc.
  • Pharmicell Co., Ltd.
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Suda Ltd
  • U.S. Stem Cell, Inc.
  • Yungjin Pharm. Co., Ltd.

발기부전 : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 병용 제품(Combination Products)별
  • 표적별
  • 작용기전별
  • 투여 방법별
  • 분자종류별

치료제 개요

  • (PDE-5 Inhibitor + tramadol hydrochloride)
    • 제품 개요
    • 작용기전
    • 연구 개발(R&D) 진전 상황
  • AdipoCell
  • alprostadil
  • AP-102
  • avanafil
  • BIO-300
  • BL-214
  • cimaglermin alfa
  • fadanafil
  • HCP-1302
  • HCP-1303
  • Immpocellgram
  • MED-2005
  • nitroglycerin
  • Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction
  • Recombinant Protein for Degenerative Disc Disease, Bone Fracture, Parkinson's Disease and Erectile Dysfunction
  • sildenafil citrate
  • Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction - Drug Profile
  • Small Molecule to Inhibit PDE5 for Erectile Dysfunction
  • SUD-003
  • Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction
  • T-6932
  • tadalafil
  • TF-0092
  • TPN-171
  • TPN-729
  • TR-399
  • udenafil
  • VLFIA-330
  • YBH-1603

발기부전 치료제 : 파이프라인 제품의 최신 동향

발기부전 치료제 : 개발 휴지 상태인 제품

발기부전 치료제 : 개발이 중지된 제품

발기부전 관련 제품 개발 마일스톤

  • 주목해야 할 최신 동향 및 프레스 릴리스

부록

도표

LSH 16.04.04

List of Tables

  • Number of Products under Development for Erectile Dysfunction, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Erectile Dysfunction - Pipeline by Adamis Pharmaceuticals Corp, H1 2019
  • Erectile Dysfunction - Pipeline by Aquestive Therapeutics Inc, H1 2019
  • Erectile Dysfunction - Pipeline by Astellas Pharma Inc, H1 2019
  • Erectile Dysfunction - Pipeline by Biozeus Pharmaceutical SA, H1 2019
  • Erectile Dysfunction - Pipeline by Can-Fite BioPharma Ltd, H1 2019
  • Erectile Dysfunction - Pipeline by Cure Pharmaceutical Inc, H1 2019
  • Erectile Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2019
  • Erectile Dysfunction - Pipeline by Futura Medical Plc, H1 2019
  • Erectile Dysfunction - Pipeline by Humanetics Corp, H1 2019
  • Erectile Dysfunction - Pipeline by Karessa Pharma Holding AB, H1 2019
  • Erectile Dysfunction - Pipeline by Mezzion Pharma Co Ltd, H1 2019
  • Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2019
  • Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd, H1 2019
  • Erectile Dysfunction - Pipeline by Pharmicell Co Ltd, H1 2019
  • Erectile Dysfunction - Pipeline by SK Chemicals Co Ltd, H1 2019
  • Erectile Dysfunction - Pipeline by Suda Pharmaceuticals Ltd, H1 2019
  • Erectile Dysfunction - Pipeline by XuanZhu Pharma Co Ltd, H1 2019
  • Erectile Dysfunction - Pipeline by Yangtze River Pharmaceutical Group, H1 2019
  • Erectile Dysfunction - Dormant Projects, H1 2019
  • Erectile Dysfunction - Dormant Projects, H1 2019 (Contd..1), H1 2019
  • Erectile Dysfunction - Dormant Projects, H1 2019 (Contd..2), H1 2019
  • Erectile Dysfunction - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Erectile Dysfunction, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Pipeline Review, H1 2019, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape.

Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Erectile Dysfunction - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 2, 5, 7, 10, 1 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Erectile Dysfunction (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Erectile Dysfunction (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Erectile Dysfunction - Overview
  • Erectile Dysfunction - Therapeutics Development
  • Erectile Dysfunction - Therapeutics Assessment
  • Erectile Dysfunction - Companies Involved in Therapeutics Development
  • Erectile Dysfunction - Drug Profiles
  • Erectile Dysfunction - Dormant Projects
  • Erectile Dysfunction - Discontinued Products
  • Erectile Dysfunction - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q
 
BCC Research